Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Background The effects of empagliflozin in patients with chronic kidney disease who are at
risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed …

Background Patients with type 2 diabetes and chronic kidney disease are at high risk for
kidney failure, cardiovascular events, and death. Whether treatment with semaglutide would …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

PUBLISHED BY ELSEVIER levels stratified by age and sex. Estimates of several summary
epidemiological measures are produced, including composite measures such as …

Background Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has
favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 …

Patients with chronic kidney disease (CKD) exhibit an elevated cardiovascular risk
manifesting as coronary artery disease, heart failure, arrhythmias, and sudden cardiac …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …